Avalo Therapeutics, Inc. (AVTX) return on equity (ROE)

Return on equity · fiscal 2025
-94.2%

Avalo Therapeutics, Inc. (AVTX) earned a return on equity of -94.2% in fiscal 2025 (the year ended December 31, 2025). That is 67.8 percentage points lower than the -26.4% of fiscal 2024. Figures as of 17 Nov 2026, 20:53 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-94.2%
Change on fiscal 2024
−67.8 pts
Highest on record
42.6%fiscal 2017
Lowest on record
-7957.2%fiscal 2016
Fiscal years on record
102015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Avalo Therapeutics, Inc. return on equity (ROE), in more detail

Across the 10 fiscal years on record (2015–2025), the highest was 42.6% in fiscal 2017 and the lowest -7957.2% in fiscal 2016. The fiscal 2025 figure is higher than in 56% of the 9 earlier fiscal years on record, whose median is -191.6%.

History · 10 fiscal years

Return on equity by fiscal year

Avalo Therapeutics, Inc. return on equity (ROE), year by year

Avalo Therapeutics, Inc. (AVTX) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-94.2% 67.8 pts down
2024-26.4% 405.5 pts up
2023-431.9%—
2021-365.5% 107.0 pts down
2020-258.5% 182.0 pts down
2019-76.6% 115.0 pts up
2018-191.6% 234.2 pts down
201742.6% 7999.8 pts up
2016-7957.2% 7877.0 pts down
2015-80.2%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on AVTX

Avalo Therapeutics, Inc., figure by figure

Avalo Therapeutics, Inc. (AVTX) overview: price, valuation and scorecard

Avalo Therapeutics, Inc. return on equity (ROE): questions and answers

What is Avalo Therapeutics, Inc.'s return on equity?

Avalo Therapeutics, Inc. (AVTX) earned a return on equity of -94.2% in fiscal 2025 (the year ended December 31, 2025). That is 67.8 percentage points lower than the -26.4% of fiscal 2024.

Is Avalo Therapeutics, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 56% of the 9 earlier fiscal years on record, whose median is -191.6%.

What are the highest and lowest return on equity figures on record for Avalo Therapeutics, Inc.?

Across the 10 fiscal years on record (2015–2025), the highest was 42.6% in fiscal 2017 and the lowest -7957.2% in fiscal 2016.

How is Avalo Therapeutics, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Avalo Therapeutics, Inc. (AVTX) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/AVTX/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.